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Background: Recent studies revealed that erythropoietin (EPO) has tissue-protective effects in the heart by
increasing vascular endothelial growth factor (VEGF) expression and attenuating myocardial fibrosis in ischemia
models. In this study, we investigated the effect of EPO on ventricular remodeling and blood vessel growth in
diabetic rats.
Methods: Male SD rats were randomly divided into 3 groups: control rats, streptozotocin (STZ)-induced diabetic
rats, and diabetic rats treated with 1000 U/kg EPO by subcutaneous injection once per week. Twelve weeks later,
echocardiography was conducted, and blood samples were collected for counting of peripheral blood endothelial
progenitor cells (EPCs). Myocardial tissues were collected, quantitative real-time PCR (RT-PCR) was used to detect
the mRNA expression of VEGF and EPO-receptor (EPOR), and Western blotting was used to detect the protein
expression of VEGF and EPOR. VEGF, EPOR, transforming growth factor beta (TGF-β), and CD31 levels in the
myocardium were determined by immunohistochemistry. To detect cardiac hypertrophy, immunohistochemistry of
collagen type I, collagen type III, and Picrosirius Red staining were performed, and cardiomyocyte cross-sectional
area was measured.
Results: After 12 weeks STZ injection, blood glucose increased significantly and remained consistently elevated.
EPO treatment significantly improved cardiac contractility and reduced diastolic dysfunction. Rats receiving the EPO
injection showed a significant increase in circulating EPCs (27.85 ± 3.43%, P< 0.01) compared with diabetic
untreated animals. EPO injection significantly increased capillary density as well as EPOR and VEGF expression in left
ventricular myocardial tissue from diabetic rats. Moreover, EPO inhibited interstitial collagen deposition and reduced
TGF-β expression.
Conclusions: Treatment with EPO protects cardiac tissue in diabetic animals by increasing VEGF and EPOR
expression levels, leading to improved revascularization and the inhibition of cardiac fibrosis.
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Diabetic cardiomyopathy (DCM) is characterized by
microvascular pathology and interstitial fibrosis, which
leads to progressive heart failure. These microvascular
abnormalities exist without hypertension and macrovas-
cular pathology, such as coronary atherosclerosis. Dia-
betic microvascular complications are considered to be
influenced by angiogenic factors, including VEGF, as a
response to both ischemia and hyperglycemia [1]. The
reduced expression of VEGF and significant reduction
in capillary density contributes to left ventricle (LV)
dysfunction in DCM [2]. Down-regulation of myocardial
VEGF expression is followed by decreased numbers of
circulating endothelial progenitor cells (EPCs), increased
apoptosis of endothelial cells, and decreased capillary
density. Hyperglycemia also causes apoptosis and necro-
sis of cardiomyocytes, along with interstitial fibrosis and
progressive cardiac dysfunction [3,4].
Recent experimental studies revealed that the hematopoietic
cytokine erythropoietin (EPO) had numerous tissue-
protective effects apart from its action on erythropoiesis
and that it prevented vascular and tissue damage caused
by acute ischemia in the heart, brain and kidneys [5].
In general, EPO stimulates normal endothelial progenitor
cell-mediated endothelial turnover, increased VEGF ex-
pression, and improved cardiac microvascularization and
function in ischemic heart [6]. EPO also ameliorates the
cardiac remodeling associated with LV pressure overload
by decreasing myocardial interstitial fibrosis [7].
Therefore, in the present study, we explored whether
the beneficial effect of EPO might be observed in the
diabetic heart. EPO and EPOR regulation in the diabetic
heart are poorly understood, and their relationship to
microvessel density, myocardial interstitial fibrosis, and
cardiac functional impairment are unclear. The present
investigation was designed to explore these issues.
Materials and methods
Animal treatment
Experiments were performed in compliance with the
ARRIVE guidelines on animal research [8]. Thirty male
SD rats weighing 220–250 g were randomly allocated
into 3 groups: (1) the control group, (2) the vehicle-
treated diabetic group, and (3) the EPO-treated diabetic
group. DM was induced by intraperitoneal injection of
50 mg/kg streptozotocin (Sigma, USA) in citrate buffer
after fasting overnight. The diabetic state was confirmed
72 h later by the determination of blood glucose concen-
trations ≥16.7 mmol/l. We previously conducted dose–
response experiments to select an appropriate dose of
EPO. In the experiments, three different doses of EPO
(500, 1000, 2000 U/kg) were used. EPO (500, 1000, or
2000 U/kg) was injected subcutaneously once a week for
12 weeks. According to the serial echocardiography resultsmeasuring LV end-diastolic diameter and ejection fraction,
we found that 1000 U/kg and 2000 U/kg of EPO were ap-
propriate dosages for cardioprotection. Considering the
increased erythrocyte levels achieved by 2000 U/kg EPO
compared with 1000 U/kg EPO, we chose 1000 U/kg EPO
for the final study. Recombinant human EPO (3SBIO
company, China) was administered by subcutaneous injec-
tion (1000 U/kg, once per week) for 12 weeks. Likewise,
the control group and the vehicle-treated diabetic group
received equal volumes of physiological saline by subcuta-
neous injection. These rats were housed for 12 weeks
under daily observation with free access to food and water.
At 12 weeks with this treatment and after echocardiog-
raphy measurements, animals were weighed, followed by
sacrificed with a lethal dose of sodium pentobarbital
(60 mg/kg i.p.) and blood samples were collected for the
erythrocyte assay and for peripheral blood EPCs counting.
Then, the heart was removed and weighed, and the LV
was dissected. Some parts of LV tissue were snap frozen,
and stored at −80°C for subsequent RT-PCR and western
blot. The remaining tissue was fixed in 10% formalin, and
paraffin was embedded for histological or immunohisto-
chemical assessment.
Echocardiography
After 12 weeks, transthoracic echocardiography was per-
formed after anesthesia with pentobarbital (40 mg/kg; i.p.)
using a commercial system (Visual Sonics Vevo 770,
VisualSonics, CA) equipped with a 12-MHz linear-array
transducer. Measurements were made offline by an obser-
ver who was blinded to the group of each animal.
Both 2-dimensional (2D) images in parasternal long-axis
and short-axis view and 2D guided M-mode tracings
were obtained. Short-axis views were recorded at the
level of mid-papillary muscles. All measurements were
obtained according to American Society of Echocardi-
ography recommendations [9]. LV end diastolic dimension
(LVD d) and LV end systolic dimension (LVD s) were
measured using M-mode. Three representative cardiac
cycles were analyzed and averaged for each measure-
ment. LV ejection fraction (EF %) was calculated using
the Teichholz method [10].
Red blood cell assay
Peripheral blood was isolated from venous blood. Red
blood cell numbers were measured by standard labora-
tory methods (hematology analyzer, BC-5800, Mindray
Bio-Med Ltd., China) at baseline and end-point.
Flow cytometry analysis
Mononuclear cells were isolated from 0.5 ml of periph-
eral venous blood by density gradient centrifugation
with Histopaque (Sigma) in six rats from each group.
Hematopoietic progenitor cells were identified by their
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positive staining for CD34 (R&D Systems) and flk-1 (Santa
Cruz Biotechnology). Cells from each animal were sus-
pended in hank’s balanced salt solution (HBSS, Invitrogen)
in the presence of phycoerythrin-labeled monoclonal
mouse anti-rat CD34(0.2 μg/μl) and fluorescein isothio-
cyanate (FITC)-labeled monoclonal mouse anti-rat flk-1
(0.1 μg/μl) for one hour. After two washes in phosphate-
buffered saline (PBS), cells were fixed in 2% formalde-
hyde/PBS before fluorescence-activated cell sorter
(FACS; FACSCalibur, Becton Dickinson, Heidelberg,
Germany) analysis. Data were analyzed using Cell-
Quest software (Becton Dickinson), and all staining
was compared to isotype-matched control antibodies
purchased from Santa Cruz.
Real time RT-PCR
Tissue samples obtained from the LV free wall were
minced. Total RNA was extracted with Trizol reagent
according to the guideline of manufacturer (Invitrogen,
USA) from the samples. For RT-PCR, cDNA was synthe-
sized in a 20 μl reaction volume containing 3 μg of total
RNA (RevertAid First Strand cDNA synthesis Kit,
Fermentas), according to the instructions of the manu-
facturer. VEGF and EPOR gene expressions were ana-
lyzed by RT-PCR using a Bio-Rad MJ Mini Opticon
Real-Time PCR System. To control for the variation in
the amount of DNA, gene expression of the target se-
quence was normalized to the expression of an endogen-
ous control, GAPDH. Primers for VEGF, EPOR and
GAPDH were constructed with the help of ShengGong
Bio-Tech Co. (Shanghai, China). The primer sequences
for real-time PCR were as follows: VEGF, 50-TATGTTT
GACTGCTGTGGACTTGA-30 and 50-CAGGGATGGG
TTTGTCGTGT-30, 204 bp; EPOR, 50-TTACCAGCTCG
AAGGTGAATCAAGA-30 and 50-GCGTCCAGGAGCA
CTACTTCATTG-30, 201 bp; GAPDH, 50-CAAGGTCA
TCCATGACAACTTTG-30 and 50-GTCCACCACCCTG
TTGCTGTAG-30, 496 bp. VEGF, EPOR and GAPDH
mRNA levels were quantified based on standard curves
(Bio-Rad CFX Manager). The results were expressed
relative to control values, which were arbitrarily assigned
a value of 1. Mean and SE were calculated using 3 inde-
pendent experiments.
Western blot assay
Proteins were extracted from the cardiac tissue obtained
from five animals of each experimental group according
to the protocol described before [11]. 20 μg of proteins
were electrophoresed through a 10% SDS-PAGE gel
and then transferred to PVDF membranes (Millipore
company, USA). The membranes were blocked in 5%
skim milk powder in PBS before overnight incubation
in a 1:400 dilution of polyclonal rabbit anti-rat VEGFantibodies, a 1:400 dilution of polyclonal rabbit anti-rat
β-actin antibodies, and a 1:400 dilution of polyclonal
rabbit anti-rat EPOR antibodies (Santa Cruz Biotechnology,
USA). Proteins were visualized using the secondary anti-
body, goat anti-rabbit IgG- horseradish peroxidase (1:5000,
Santa Cruz Biotechnology, USA), followed by an enhanced
chemiluminescence reagent (Western Blotting Chemilu-
minescence Luminol reagent; Santa Cruz Biotechnology,
USA) and exposed to Canon EOS 60D film (USA). The
proteins were quantified with the Image tool 3.0 analyze
system. The results were expressed as densitometric ana-
lysis of VEGF and EPOR bands normalized to endogenous
control, β-actin expression. Mean and SE were calculated
using 3 independent experiments.
Immunohistochemistry
Four-micrometer serial paraffin sections of LV were
stained with polyclonal rabbit anti-rat VEGF, EPOR and
TGF-β antibodies (Santa Cruz Biotechnology, USA,
1:200). The staining was visualized by reaction with
3,3-diaminobenzidine tetrahydrochloride (DAB; Sigma
Chemical Co., USA, 1:20). The specimens were then
lightly counterstained with Mayer’s hematoxylin, dehy-
drated, and xylene-based mounted under glass cover
slips. Brown colored sites were quantified at a final
magnification of 400× with a microscope connected
to a video camera. We found that the positive stain-
ing most in the epithelium and blood vessels area.
The content of positive staining area was averaged on
ten fields selected across the wall thickness in the
septum and free wall. Negative controls were treated
as above, but a solution of PBS replaced the primary
antibody. All images were reviewed under light micro-
scope (Scope.A1; Zeiss, Germany) with an independent
pathologist. Computer-assisted morphometry was per-
formed with Image Pro Plus 5.0.
Capillary vessels
To visualize the capillaries in the myocardium, endothe-
lial cells were stained with CD31, often used as a bio-
logical marker to represent the capillary vessels in
myocardium. Angiogenesis was quantitatively assessed by
CD31-positive staining capillary vessels for the determin-
ation of capillary density. For immunostaining, rabbit
anti-rat CD31 antibody (Santa Cruz Biotechnology, USA,
1:100) was used. The staining was visualized by reaction
with DAB (Sigma Chemical Co., USA, 1:20). Capillaries
were visualized in the myocardium as a brown precipitate,
identified as having a diameter <20 μm and a layer of
endothelial cells without smooth muscle cells. To deter-
mine capillary density, the number of positive staining
was counted in a doubleblind fashion from ten different
fields of each section (n= 5) at × 400 magnification. The
average number of the vessels in one section was used for
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under light microscope (Scope.A1; Zeiss, Germany) with an
independent pathologist. Computer-assisted morphometry
was performed with Image Pro Plus 5.0.
Determination of fibrosis
LV samples were embedded in paraffin, sectioned at
5 μm and stained for 1 h in the Picrosirius solution
(0.1% solution of Sirius Red F3BA in saturated aqueous
picric acid). The stained sections were then washed for
2 min in 0.01 M HCL, dehydrated, cleared and mounted
in synthetic resin. Micrographs were used to calculate
the collagen content in the myocardial interstitium.
Four-micrometer serial paraffin sections of LV were
stained with polyclonal rabbit anti-rat collagen typeI
antibody (Santa Cruz Biotechnology, USA, 1:50). and
collagen type III antibody (Santa Cruz Biotechnology,
USA, 1:100). The staining was visualized by reaction with
3,3-diaminobenzidine tetrahydrochloride (DAB; Sigma
Chemical Co., USA, 1:20). We found that the positive
staining most in the interstitial and perivascular area.
Brown colored sites were quantified at a final magnifica-
tion of 400× with a microscope connected to a video
camera. The content of positive staining area was averaged
on ten fields selected across the wall thickness in the
septum and free wall. Negative controls were treated as
above, but a solution of PBS replaced the primary antibody.
All images were reviewed under light microscope
(Scope.A1; Zeiss, Germany) with an independent path-
ologist. Computer-assisted morphometry was performed
with Image Pro Plus 5.0. A mean of 10 randomly selected
fields were counted for each section.
Cardiomyocyte size
Four-micrometer serial paraffin sections of LV were stained
with hematoxylin-eosin to determine cardiomyocyte cross-
sectional area. In longitudinally oriented cardiomyocytes,Table 1 General characteristics of the animal model (mean ±
Parameters Controls (n = 8)
LVD d (mm) 6.62 ± 0.36
LVD s (mm) 3.57 ± 0.58
EF (%) 79.4 ± 8.12
Body weight (g) baseline 236± 7.9
Body weight (g) end-point 358± 13.8
Heart rate (BPM) 411.8 ± 46.8
HW/BW (mg/g) 3.1 ± 0.14
Blood glucose (mmol/L) baseline 4.55 ± 0.60
Blood glucose (mmol/L) end-point 4.13 ± 0.43
Erythrocyte numbers (1012/L) baseline 8.00 ± 0.43
Erythrocyte numbers (1012/L) end-point 8.16 ± 0.37
*P< 0.05 vs control, #P <0.01 vs control, ▲P <0.05 vs diabetes.cardiomyocyte cross-sectional area was measured in a
doubleblind fashion from ten different sites of each section
(n=5) at × 400 magnification. All images were reviewed
under light microscope (Scope.A1; Zeiss, Germany)
with an independent pathologist. Computer-assisted
morphometry was performed with Image Pro Plus 5.0.
Statistical analysis
Data are expressed as the means ± SE. Statistical analysis
was performed with the SPSS statistical software (version
17.0, SPSS). Between-group comparisons of means were
performed by one-way analysis of variance (ANOVA)
followed by Turkey post-hoc test. P< 0.05 was considered
statistically significant.
Results
Recovery of cardiac function in DCM after administration
of EPO
Four rats died during the treatment period, two in the
vehicle-treated diabetic group and two in the EPO-
treated group. Metabolic and hemodynamic parameters
for all animal groups are presented in Table 1. Trans-
thoracic echocardiographic examination was performed.
Ejection fraction was greatly decreased in the vehicle-
treated diabetic rats compared with the control group,
which meant that LV systolic function was significantly
decreased in diabetic rats. LVD d and LVD s were no-
ticeably increased in the diabetic group compared with the
control group (LVD d (mm): 7.48± 0.72 vs 6.62± 0.36,
LVD s (mm): 4.65 ± 0.74 vs 3.57± 0.58, P< 0.05). EPO
treatment attenuated LV dilatation and dysfunction com-
pared to the vehicle-treated diabetic group. Ejection frac-
tion was significantly increased and LVD d and LVD s
were noticeably decreased in the EPO-treated diabetic rats
compared with the vehicle-treated diabetic rats. Body
weight was significantly decreased in diabetic rats com-
pared with the control group. Administration of EPOSEM)
DM rats (n = 8) DM+EPO rats (n = 8)
7.48 ± 0.72* 6.78 ± 0.53▲
4.65 ± 0.74* 3.67 ± 0.65▲
65.7 ± 5.49# 75.6 ± 4.87▲
241± 6.7 239 ± 8.8
293± 13.5# 332 ± 15.4▲
416.6 ± 67.2 376.9 ± 43.0
4.5 ± 0.20# 3.3 ± 0.18▲
20.47 ± 1.46# 20.63 ± 1.62#
20.27 ± 1.20# 21.37 ± 1.53#
7.84 ± 0.40 8.06 ± 0.23
7.68 ± 0.34 8.23 ± 0.47
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heart weight indexed to body weight (HW/BW) was sig-
nificantly increased in diabetic rats compared with the
control group. Administration of EPO reduced the HW/
BW of the diabetic rats. Blood glucose increased signifi-
cantly and remained consistently elevated. We observed
that EPO did not change plasma glucose levels in diabetic
rats. We also observed no significant differences in
erythrocyte levels between the diabetic group and the
EPO-treated diabetic group.
EPO increased the number of EPCs
To determine the effect of the EPO on EPC mobilization,
we analyzed EPC-like peripheral blood mononuclear cells
(PBMCs) by flow cytometry. EPC-like PBMCs were identi-
fied by positive staining for CD34 and Flk-1. As shown in
Figure 1, CD34+/flk-1+ mononuclear cells in diabetic rats
decreased compared with the control group (2.71± 0.74%
vs. 7.65± 0.89%, P <0.01). Importantly, rats receiving the
EPO injection showed a significant increase in circulating
CD34+/flk-1+ mononuclear cells (27.85± 3.43%, P< 0.01)
compared with animals treated with PBS.
EPO increased VEGF and EPOR mRNA and protein
expression in diabetic myocardial tissue
We next determined myocardial VEGF and EPOR mRNA
expression and protein content using quantitative real-
























Figure 1 EPO administration increased the number of CD34+Flk-1+ pr
rats, DM rats, and EPO rats. (B): Tabulated data. #P <0.01 vs control, △P <0.0detected VEGF and EPOR expression in myocardium by
immunohistochemical method. As shown in Figure 2D,
diabetic rats had significantly decreased VEGF and EPOR
mRNA relative level compared with the control rats
(VEGF mRNA: 0.73± 0.10 vs. 0.99± 0.10, P <0.01; EPOR
mRNA: 0.82± 0.07 vs. 1.01 ± 0.15, P <0.05). VEGF and
EPOR mRNA relative levels in EPO-treated diabetic group
were significantly higher than in vehicle-treated diabetic
rats (VEGF mRNA: 1.32 ± 0.07 vs. 0.73± 0.10, EPOR
mRNA: 1.18 ± 0.11 vs. 0.82± 0.07, P <0.01), and higher
than in control group (VEGF mRNA: P <0.01; EPOR
mRNA: P <0.05). As shown in Figure 2C, diabetic rats had
significantly decreased VEGF and EPOR protein relative
level compared with the control rats (VEGF protein:
0.25± 0.03 vs. 0.39± 0.04, EPOR protein: 0.26± 0.04
vs. 0.42± 0.05, P <0.01). However, EPO treatment of
diabetic rats resulted in significantly enhanced VEGF and
EPOR protein expression compared with the diabetic rats
(VEGF protein: 0.57 ± 0.04 vs. 0.25± 0.03, EPOR protein:
0.55± 0.05 vs. 0.26± 0.04, P <0.01) and significantly higher
VEGF and EPOR protein expression compared with the
control rats(P <0.01). As shown in Figure 2B, diabetic rats
had significantly decreased VEGF and EPOR immu-
nostaining compared with the control rats (VEGF:
5.58 ± 0.59% vs. 10.8 ± 1.16%; EPOR: 0.72 ± 0.07% vs.
1.07± 0.17%, P <0.01). VEGF and EPOR immunostaining
in EPO-treated diabetic group were significantly higher

























































































































































Figure 2 (See legend on next page.)
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Figure 2 EPO administration increased angiogenesis in diabetic rats and was dependent on VEGF and EPOR up-regulation. (A)
Representative micrographs of heart sections stained with antibodies against CD31, EPOR and VEGF (400x magnification). (B) Capillary density in
number of capillaries per mm2. Quantitative data showed EPOR and VEGF staining. (C) Representative western blots of myocardial VEGF and
EPOR levels. (D) Real-time PCR analysis of VEGF and EPOR mRNA levels. Data are expressed as the mean ± SEM (n = 5). *P< 0.05 vs control,
#P <0.01 vs control, ▲P <0.05 vs diabetes, △P <0.01 vs diabetes.
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P <0.01), and the difference between the EPO-treated
group and the control group is not significant (P >0.05).
Capillary density
As shown in Figure 2B, quantitative analysis showed that
induction of DM significantly reduced cardiac capillary
density in diabetic rats compared with the control group
(373.4 ± 41.7 mm2 vs. 460.6 ± 51.6 mm2, P < 0.01). EPO
significantly increased capillary density in DM rats
(482.4 ± 44.0 mm2 vs. 373.4 ± 41.7 mm2, P < 0.01). The
difference between the EPO-treated group and the control
group is not significant (P >0.05).
EPO attenuates myocardial interstitial fibrosis and
cardiomyocyte hypertrophy in diabetic rats
TGF-β plays a pivotal role in the pathogenesis of fibrotic
effects accompanying diabetic complications. Immuno-
histochemical staining for TGF-β demonstrated a similar
pattern to that observed with respect to collagen con-
tent. As shown in Figure 3C, diabetic rats had signifi-
cantly increased TGF-β immunostaining compared with
the control rats (7.76 ± 0.72% vs. 0.72 ± 0.06%, P <0.01).
TGF-β immunostaining in EPO-treated diabetic group
were significantly lower than in vehicle-treated diabetic
rats (1.48 ± 0.35% vs. 7.76 ± 0.72%, P <0.01), but signifi-
cantly higher compared with the control rats (P < 0.05).
To assess the extent of myocardial interstitial fibrosis,
we measured the collagen content by Picrosirius Red
staining in sections of LV from experimental animals
(Figure 3A). As shown in Figure 3B, quantitative analysis
of the fibrotic region of LV myocardium stained with
Picrosirius Red indicated significantly increased intersti-
tial fibrosis in DM animals versus control (12.1 ± 0.43%
vs. 2.80 ± 0.51%, P <0.01). EPO treatment significantly
reduced the extent of myocardial interstitial fibrosis
compared with the diabetic rats (5.96 ± 0.32% vs.
12.1 ± 0.43%, P <0.01), but significantly higher compared
with the control rats (P < 0.01).
Myocyte cross-sectional area (an indication of cardio-
myocyte hypertrophy) was significantly increased in dia-
betic rats compared to control rats and this was
accompanied by increased abundance in myocardial col-
lagen (an indication of cardiac fibrosis). EPO treatment
prevented these changes. As shown in Figure 3D, quanti-
tative analysis of the fibrotic region of LV myocardiumstained with collagen type I indicated significantly
increased interstitial fibrosis in DM animals versus con-
trol(20.29 ± 5.62% vs. 4.97 ± 1.12%, P <0.01). EPO treat-
ment significantly reduced the extent of collagen type I
compared with the diabetic rats (12.96 ± 3.51% vs.
20.29 ± 5.62%, P <0.01), but significantly higher com-
pared with the control rats (P < 0.01). As shown in
Figure 3E, quantitative analysis of the fibrotic region
of LV myocardium stained with collagen type III
significantly increased in DM animals versus control
(12.07± 3.17% vs. 2.73 ± 0.56%, P <0.01). EPO treatment
significantly attenuated the extent of collagen type III
compared with the diabetic rats (5.80 ± 1.17% vs.
12.07± 3.17%, P <0.01), but significantly higher compared
with the control rats (P< 0.05). As shown in Figure 3F, car-
diomyocyte cross-sectional area significantly increased in
DM animals versus control (295.33±13.52 μm2 vs.
181.5±15.41 μm2, P <0.01). EPO treatment significantly
attenuated cardiomyocyte hypertrophy compared with
the diabetic rats (258.33±10.23 μm2 vs. 295.33±13.52 μm2,
P <0.01), but significantly higher compared with the control
rats (P<0.01).
Discussion
In the present study, we observed the DCM at the func-
tional, histomorphological, and molecular level. Through
our studies with EPO in DCM rats, we found that the
administration of EPO could improve cardiac function
and reverse remodeling of the heart of DCM rats by en-
hancing angiogenesis and attenuating interstitial fibrosis
without affecting blood glucose.
EPO increases myocardial angiogenesis
Decreased capillary density has been described in hearts
of diabetic mice and patients, and hypothesized as an
important mechanism of DCM [3,12,13]. Our present
study found that capillary density in diabetic myocardial
tissue was significantly decreased and we documented
decreased numbers of circulating EPCs and VEGF ex-
pression in DCM. It is now becoming increasingly clear
that EPO plays a protective role in the body outside of
its erythropoietic effects. Previous studies identified the
protective effects of EPO on different molecular path-
ways in ischemic tissues in the heart, kidney, and brain
[5,14,15]. There are very few studies describing an effect
of EPO treatment on diabetic cardiac tissue [16]. Here,
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Figure 3 EPO inhibited myocardial fibrosis and cardiomyocyte hypertrophy in diabetic rats and was dependent on the reduction of
TGF-β expression. (A) Picrosirius Red staining showing the collagen content in LV sections from control, diabetic, and diabetic EPO–treated rats.
The arrowhead indicates elevated collagen content that was stained red in the extracellular matrix in the LV myocardium of diabetic rats and is
significantly higher than control and EPO–treated group (200×magnification). (B) Collagen content was quantified from Picrosirius Red staining
using Adobe Photoshop. (C) Immunohistochemical staining of TGF-β: quantitative data of TGF-β staining (400× magnification).
(D) Immunohistochemical staining of collagen type I: quantitative data of collagen type I staining (400× magnification). (E) Immunohistochemical
staining of collagen type III: quantitative data of collagen type III staining (400× magnification). (F) Caridomyocyte size was measured by
hematoxylin-eosin staining in cross-sectional areas. (400× magnification). Bar graph shows quantitative analysis of cardiomyocyte cross-sectional
area. Data are expressed as the mean ± SEM (n = 5).*P< 0.05 vs control, #P <0.01 vs control, ▲P <0.05 vs diabetes, △P <0.01 vs diabetes.
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tective effect against diabetic cardiac damage. Our data
showed that EPO could promote angiogenesis in DCM,
independent of its erythropoietic effects. Recent studies
found that EPO promoted angiogenesis in the ischemic
myocardium by a number of mechanisims including EPCproliferation, mobilization, homing and incorporation into
the endothelium, and this was dependent upon a PI3-
kinase and Akt pathway [17]. Westenbrink BD, et al.,
found that EPO promoted VEGF transcription through
the JAK2/STAT-3 signal transduction pathway under is-
chemic conditions [18]. Several studies provided evidence
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thelial cell proliferation, and reduced endothelial cell
apoptosis through endothelin-1 release [19]. Endothelin-1
can increase the expression of VEGF via protein kin-
ase C (PKC). Other studies found that EPO promoted
vessel formation associated with JAK-2 phosphoryl-
ation and matrix metalloproteinase-2 (MMP-2) pro-
duction and EPO increased capillary growth to a level
similar to that of VEGF. Some previous studies showed
that in chronic post-myocardial infarction(MI) heart fail-
ure models, EPO increased incorporation of EPCs into the
myocardial microvasculature and improved neovasculari-
zation, which was associated with increased EPOR and
VEGF expression in ischemic hearts [6,20]. However, up-
regulation of VEGF at sites of EPO-induced neovasculari-
zation in ischemic tissues has been substantiated in other
reports [21-23]. It is reported that EPO-induced VEGF
up-regulation is mediated through EPOR signaling path-
ways [24-26] and VEGF can stimulate proliferation of
endothelial cells and has important chemotactic effects on
EPCs [25,27,28]. Taken together, though these studies pro-
vided clear evidence for promotion of neovasclarization by
EPO, the exact molecular mechanisims has not been fully
elucidated. Our study showed that EPO treatment signifi-
cantly enhanced myocardial VEGF and EPOR expression,
and significantly increased numbers of circulating EPCs.
We presumed that EPO increased VEGF expression
through EPOR signaling, augmenting EPCs number, medi-
ating the preferential homing of EPCs into the diabetic
heart tissue, and improving myocardial neovascularization
in DCM.
EPO attenuates myocardial interstitial fibrosis and
cardiomyocyte hypertrophy
Interstitial and perivascular fibrosis is a histological hall-
mark of DCM [29,30], and pathological hypertrophy of car-
diomyocytes often accompanies it. Our findings showed
myocardial interstitial fibrosis and cardiomyocyte hyper-
trophy in DCM. Increasing evidence suggests that EPO
ameliorates cardiac remodeling and improves cardiac func-
tion by exerting anti-fibrotic effects in the myocardial
ischemia model, but the underlying mechanism has
not been totally elucidated. Wang W et al. documen-
ted that the EPO-EPOR system mediated accelerated
phosphorylation of STAT3, Akt and eNOS and depressed
phosphorylation of p38, resulting in prevention of myocar-
dial fibrosis [7]. Several studies found that EPO treatment
prevented extracellular matrix disruption in ischemia/
reperfusion (I/R) injury and decreased collagen degradation
and improved heart function. Moreover, improved myocar-
dial neovascularization by VEGF expression may have
another potential advantage for treatment of DCM by
increasing capillary density in more fibrotic areas [3].
It is reported that the mediator of extracellular matrixproduction, TGF-β, can stimulate collagen production
and contribute fibrosis in DCM [31]. Our data showed
that EPO reduced the collagen type I, III deposition in
DCM and down-regulated TGF-β expression. It is highly
possible that EPO treatment led to a reduction in TGF-β
expression and attenuated the hypertrophic growth of
the diabetic heart.
EPO improves cardiac function
In the present study, at 12 weeks post-DM, the LV systolic
function was significantly decreased in DCM. After EPO
administration, LVD d and LVD s were all significantly
decreased, and cardiac function improved. In several stud-
ies, angiogenesis has been shown to improve heart func-
tion in dilated cardiomyopathy, pressure-overload induced
hypertrophy, and following MI. Our results suggested that
increasing angiogenesis effect might contribute to myocar-
dial protection of EPO. It was known that myocardial
fibrosis could cause myocardial dysfunction in diabetes. In
addition to the increase in collagen deposition, cross-
linking of collagen fibers may be increased by diabetes,
contributing to reduction in ventricular compliance. Our
findings suggested that EPO attenuated cardiac re-
modeling and improved cardiac function by exerting
anti-fibrotic effects.
The mechanisms of cardiac dysfunction induced by
diabetes are still controversial, but multiple factors may
contribute to LV dysfunction. In particular, impairments
in excitation–contraction coupling, such as reduction of
sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a), are
important for ventricular dysfunction in diabetes. Down-
regulation of SERCA2a is a primary mechanism of
reduced Ca2+ uptake, which impairs excitation–contraction
coupling leading to cardiac dysfunction. It is reported
that EPO restored and augmented extracellular signal-
regulated kinase (ERK) activity and activated ERK phos-
phorylated GATA-4 to enhance its DNA binding and tran-
scriptional activation in cardiomyopathy models. ERK
activity is important for stimulating GATA-4-dependent
sarcomeric protein synthesis and inhibiting sarcomeric
protein degradation [32]. We speculated that increased
sarcomeric protein synthesis by EPO was associated with
the up-regulation of SERCA2a in sarcoplasmic reticulum
to improve cardiac function in DCM. Further investiga-
tions to elucidate the molecular signals in their regulation
by EPO would seem warranted.
Limitations
We did not include a control group treated with EPO,
so we cannot evaluate the effect of EPO on control
(non-diabetic) animals. Furthermore, the effect of EPO
on other mechanisms implicated in the pathogenesis of
DCM should be explored, such as the apoptosis markers,
the SERCA2a protein expression, the inflammatory
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VEGF expression, and so on. Although a chronic rat
model that tested the effect of EPO was used in the
present study, there were some reports showing that pro-
tective cellular signaling of EPO treatment was disturbed
in diabetes. One of the possible explanations for this dis-
crepancy is the use of EPO at different time points and
durations. Ghaboura N, et al. found that a single adminis-
tration of darbepoetin alfa 5000 U/kg at the onset of the
reperfusion decreased infarct size at 2 h after MI, which
evaluated the acute cardio-protective effect of the EPO ad-
ministration . Our group administered EPO 1000 U/kg,
once a week after DM, for 12 weeks. The EPO treatment
duration in our study was rather longer to exert its cardiac
protective effects in diabetes. Further studies should be
conducted to compare the effects of EPO at different
doses and different time points in diabetic models.
Conclusion
We observed a significant reduction in microvessel
density and increased myocardial fibrosis in diabetic rats.
EPO prevented the pathological changes and cardiac
dysfunction through enhancing angiogenesis and attenu-
ating interstitial fibrosis in DCM.
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